• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Coronavirus
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
IVIG
Immunization
Immuno-oncology
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

September 6, 2022

Intravenous Immunoglobulin May Accelerate Platelet Count Stabilization, Recovery in Obinutuzumab-Related Thrombocytopenia

Author(s):

Lindsey Mulrooney

Complete recovery of platelet counts after obinutuzumab-based therapy was found to be associated with, or accelerated by, intravenous immunoglobulin.

Intravenous immunoglobulin (IVIG) treatment may accelerate platelet count stabilization and recovery in obinutuzumab- or anti-CD20 monoclonal antibody (mAb)-related thrombocytopenia, according to a case report published in Hemasphere. However, close-meshed monitoring of platelet counts is still recommended for patients undergoing an anti-CD20 mAb treatment.

Targeted anti-CD20 treatment is effectively used in B-cell neoplasia, such as follicular lymphoma (FL). In combination with chemotherapy, the third-generation anti-CD20 mAb obinutuzumab prolonged progression-free survival compared to a rituximab-based therapy in patients with FL.

Obinutuzumab especially benefitted patients with risk factors such as age > 60 years, > 4 nodal sites, elevated lactate dehydrogenase (LDH), hemoglobin <120 g/L, Ann Arbor stage III–IV, leading to an intermediate or high FL International Prognostic Index (FLIPI).

In the case report, a 56-year-old female presented with progressive dyspnea and FL initially diagnosed 1 week prior to the admission. During an inpatient treatment of myocardial infarction 3 weeks preadmission, 2 drug-eluting stents were implanted in the ramus circumflexus within percutaneous coronary intervention.

After, the patient received an oral dual antiplatelet therapy with acetylsalicylic acid (ASA) 100 mg and clopidogrel 75 mg daily. Computer tomography identified ascites and an extensive axillary, clavicular, mediastinal, retroperitoneal lymphadenectomy FL grade 1-2 at initial diagnosis.

Ascites was also possibly associated with FL throughout cytological examination. A bone marrow infiltration up to 20% was detected histologically. FLIPI reached 4 points, indicating a high risk due to the involvements of > 4 nodal sites, a slightly elevated LDH, a hemoglobin <120 g/L, and an Ann Arbor stage IV.

At the time of admission, the patient complained about progressive dyspnea, edema of the lower legs, an increasing abdominal circumference, and a weight gain of about 6 kg over the last week. Night sweats were also reported to occur frequently.

Initial blood count analysis revealed leukocyte count 11.4 × 109/L (4–10 × 109/L), hemoglobin 109.5 g/L (120–160 g/L), and platelet count 245 × 109/L (150–375 × 109/L). A rapid improvement in dyspnea was observed after therapeutic abdominal paracentesis of about 2000 mL ascites and intravenous furosemide therapy.

After a pre-phase treatment with prednisolone, a decision was made to initiate an immunochemotherapy with obinutuzumab and bendamustine. Bendamustine was administered via IV infusion at a dose of 155 mg (90mg/m2) on days 1 and 2.

Due to high tumor burden, obinutuzumab infusion was split to decrease the risk of infusion-related reactions. Physicians administered obinutuzumab as an intravenous infusion at a dose of 100 mg on day 1 (100 mg absolute, 25 mg/h) and 900 mg on day 2 (900 mg absolute, 50 mg/h, increased in increments of 50 mg/h every 30 min up to a maximum of 400 mg/h).

The patient received premedication with paracetamol 1000 mg orally, prednisolone 100 mg, and clemastine 2 mg intravenously about 1 hour before obinutuzumab administration on days 1 and 2. Overall, the treatment was well tolerated; however, the patient experienced mild chills on day 1 during obinutuzumab application.

Within 1 day after immunochemotherapy, the patient developed a marked thrombocytopenia with a platelet count of 19 × 109/L. Thrombocytopenia was confirmed in the control measurements, platelet aggregates, and fragmentocytes were microscopically excluded.

No evidence of type II heparin-induced thrombocytopenia (HIT) or disseminated intravascular coagulation (DIC) was found. Type II HIT was considered less likely because no heparin had been administered since myocardial infarction 3 weeks preadmission. Additionally, no IgG class antibodies against the complex of platelet factor 4 and heparin were detected.

Coagulation parameters were found to remain unaffected over time: prothrombin time (PT) 77% (> 70%), international normalized ratio 1.18 (< 1.15), activated partial thromboplastin time (aPTT) 27.3 seconds (< 34.4 s), thrombin time 14.7 seconds (< 18.5 s), and fibrinogen 3.65 g/L (1.5–4.0 g/L).

DIC was deemed unlikely as no drop of PT or fibrinogen or prolonged aPTT became apparent. Platelet counts reached its lower level with 4 × 109/L 2 days after immunochemotherapy. The dual antiplatelet therapy was indispensable early after coronary stent implantation in the prevention of in-stent thrombosis and reinfarction.

Under a close and constant risk-benefit consideration of antiplatelet therapy and bleeding complications, the risk of in-stent thrombosis and reinfarction was considered as leading. On the recommendation of cardiological colleagues, the physicians decided to continue clopidogrel and discontinue ASA for 1 day.

In addition, 3 platelet concentrates were transfused. The concentration of IgG was found to be slightly reduced with 5 g/L. Due to suspicion of an immune-mediated, obinutuzumab-related thrombocytopenia, IVIG 10 g daily was administered for 3 days. No additional therapy with corticosteroids was performed.

IgG concentration increased to 6.24 g/L. Platelet counts spontaneously increased on day 4, and then completely recovered on day 6 after immunochemotherapy. No signs of bleeding occurred during thrombocytopenia and the patient was discharged without complications.

Though the physicians refrained from further obinutuzumab administration, immunochemotherapy was continued on time using rituximab and bendamustine with platelet counts unaffected. Therapy is still ongoing for this patient.

In the GALLIUM trial, 11.4% of patients administered obinutuzumab experienced thrombocytopenia, opposed to 7.5% of rituximab-treated patients. However, thrombocytopenia is not specifically obinutuzumab-related, but more commonly observed in patients receiving obinutuzumab-based regimens, according to the study authors.

Thrombocytopenia occurring within 24 hours after immunotherapy was considered acute. Thrombocytopenia most frequently occurred during induction therapy. Moreover, infusion-related reactions, such as acute thrombocytopenia, were most common after the first infusion of anti-CD20 mAb.

Obinutuzumab-related acute thrombocytopenia occurring within 24 hours after administration of obinutuzumab is a sudden and severe event.

The authors note that it remains unclear whether complete recovery of platelet counts after obinutuzumab-based therapy in this case was solely due to applying IVIG. However, they suggest that IVIG may accelerate platelet count stabilization and recovery in obinutuzumab- or anti-CD20 mAb-related thrombocytopenia in general.

However, they recommend close-meshed monitoring of platelet counts within patients undergoing an anti-CD20 mAb treatment, especially considering that a marked infusion-related reaction does not necessarily precede acute thrombocytopenia.

Reference

Haage T R, Surov A, Mougiakakos D, Berisha M. Successful use of intravenous immunoglobulins in an obinutuzumab-related acute thrombocytopenia. Hemasphere. 2022;6(8):e751. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351898/. Published July 15, 2022. Accessed August 17, 2022.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Image credit: Photo18@desing | stock.dobe.com
Related Content
Advertisement
Pills spilled on United States dollars | Image Credit: © RomanR - stock.adobe.com
May 13th 2025

President Trump Signs Executive Order Aiming to Lower Prescription Drug Costs by Up to 90%

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Doctor hold Blood sample for Primary Immunodeficiency (PID) test. Medical testing concept with laboratory background.
May 13th 2025

Mild to Moderate Adverse Events Possible in Pediatric Patients With Primary Immunodeficiency Receiving IVIG

Luke Halpern, Assistant Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Patient and health care professional -- Image credit: lordn | stock.adobe.com
May 12th 2025

Patient-Centered Value is Essential Within Health Care Research

Gillian McGovern, Associate Editor
Pharmacist Champion Role Improves Access to Resmetirom for MASH
May 12th 2025

Pharmacist Champion Role Improves Access to Resmetirom for MASH

Brian Gaul, PharmD
Related Content
Advertisement
Pills spilled on United States dollars | Image Credit: © RomanR - stock.adobe.com
May 13th 2025

President Trump Signs Executive Order Aiming to Lower Prescription Drug Costs by Up to 90%

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Doctor hold Blood sample for Primary Immunodeficiency (PID) test. Medical testing concept with laboratory background.
May 13th 2025

Mild to Moderate Adverse Events Possible in Pediatric Patients With Primary Immunodeficiency Receiving IVIG

Luke Halpern, Assistant Editor
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
Patient and health care professional -- Image credit: lordn | stock.adobe.com
May 12th 2025

Patient-Centered Value is Essential Within Health Care Research

Gillian McGovern, Associate Editor
Pharmacist Champion Role Improves Access to Resmetirom for MASH
May 12th 2025

Pharmacist Champion Role Improves Access to Resmetirom for MASH

Brian Gaul, PharmD
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.